Nebivolol inhibits human aortic smooth muscle cell growth: Effects on cell cycle regulatory proteins

Journal of Cardiovascular Pharmacology

Volumn 35, Issue 6, 2000, Pages 845-848

  André, Dominique E ^a   Arnet, Urs ^a,b   Yang, Zhihong ^a,c   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Merck Sharp and Dohme Chibret AG   (Switzerland)

^c UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Blocker; Cdk2; MAPK; PRb; S6K

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; NEBIVOLOL; PROTEIN P27; REGULATOR PROTEIN; S6 KINASE;

ARTICLE; CARDIOVASCULAR DISEASE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HEMODYNAMICS; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOBLOTTING; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ADRENERGIC BETA-ANTAGONISTS; AORTA; ATENOLOL; BENZOPYRANS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL DIVISION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME ACTIVATION; ETHANOLAMINES; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MUSCLE, SMOOTH, VASCULAR; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; RIBOSOMAL PROTEIN S6 KINASES; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0034035071     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200006000-00003     Document Type: Article

References (9)

1. 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552-63.
2. Stoleru L, Wijns W, Van Eyll C, Bouvy T, Van Nueten L, Pouleur H. Effects of d-nebivolol and l-nebivolol on left ventricular systolic and diastolic function: comparison with dl-nebivolol and atenolol. J Cardiovasc Pharmacol 1993;22:183-90.
3. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71.
4. Van Bortel LMAB, van Baak MA. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drugs Ther 1992;6:239-47.
5. Nava E, Farre AL, Moreno C, et al. Alterations to the nitric oxide pathway in the spontaneously hypertensive rat. J Hypertens 1998; 16:609-15.
6. Ruschitzka F, Corti R, Noll G, Luscher TF. A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens 1999;(suppl 17):S25-35.
7. Scott-Burden T, Resink TJ, Buhler FR. Enhanced growth and growth factor responsiveness of vascular smooth muscle cells from hypertensive rats. J Cardiovasc Pharmacol 1989;(suppl 14):S16-21.
8. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-6.
9. S6K: mechanisms of activation and role in mitogenesis. Semin Cancer Biol 1994;5:255-60.